These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 8634067)

  • 21. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense inhibition of phosphodiesterase expression.
    Epstein PM
    Methods; 1998 Jan; 14(1):21-33. PubMed ID: 9500855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
    Mirabelli CK; Bennett CF; Anderson K; Crooke ST
    Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
    Olie RA; Zangemeister-Wittke U
    Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense technology and prospects for therapy of viral infections and cancer.
    Wagner RW; Flanagan WM
    Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
    Gewirtz AM
    Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
    Brysch W; Schlingensiepen KH
    Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene inhibition using antisense oligodeoxynucleotides.
    Wagner RW
    Nature; 1994 Nov; 372(6504):333-5. PubMed ID: 7969490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense strategies in the treatment of leukemias.
    Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
    Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotides.
    Calabretta B; Skorski T; Zon G
    Semin Cancer Biol; 1992 Dec; 3(6):391-8. PubMed ID: 1286160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.